Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Ubrogepant

    Menu

    Ubrogepant

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              AbbVie Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022

              Details:

              UBRELVY® (Ubrogepant), is an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine with or without aura in adults that is an option for a wide range of patients who experience migraine attacks.

              Lead Product(s): Ubrogepant

              Therapeutic Area: Neurology Product Name: Ubrelvy

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 08, 2022

              Abbvie Company Banner

              WBC 2024

              Not Confirmed

              envelop Contact Supplier

              AbbVie Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Contact Supplier Contact Supplier
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting

              Details:

              AbbVie's investigational preventive treatment of migraine in adults who meet criteria for episodic migraine, as well as data on UBRELVY® (ubrogepant) and BOTOX® (onabotulinumtoxinA).

              Lead Product(s): Ubrogepant

              Therapeutic Area: Neurology Product Name: Ubrelvy

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 26, 2021

              Abbvie Company Banner

              WBC 2024

              Not Confirmed

              envelop Contact Supplier
              PMC Isochem Ubrogepant
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Close
              4
              Post Enquiry
              POST ENQUIRY